Advertisement

Topics

Latest "Odonate Therapeutics" News Stories

03:38 EDT 21st May 2018 | BioPortfolio

Here are the most relevant search results for "Odonate Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Odonate Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Odonate Therapeutics for you to read. Along with our medical data and news we also list Odonate Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odonate Therapeutics Companies for you to search.

Showing "Odonate Therapeutics" News Articles 1–25 of 6,400+

Extremely Relevant

Deals this week: Odonate Therapeutics, China Reform Holdings, Denali Therapeutics

US-based therapeutics developer Odonate Therapeutics LLC plans to raise $182.57m through an initial public offering (IPO) of 6,762,000 shares of...Read More... The post Deals this week: Odonate Therapeutics, China Reform Holdings, Denali Therapeutics appeared first on Drug Development Technology.


Odonate begins Phase lll trial of tesetaxel to treat MBC

Odonate Therapeutics has started a new Phase lll trial of tesetaxel in patients with locally advanced or metastatic breast cancer...Read More... The post Odonate begins Phase lll trial of tesetaxel to treat MBC appeared first on Drug Development Technology.

Odonate nets $139.5mm through initial public offering

Odonate Therapeutics LLC (cancer drug development) netted $139.5mm through its initial public offering of 6.25mm common share...


Relevant

Disrupting Breast Cancer Paradigms - Odonate Therapeutics

Odonate Therapeutics Announces Pricing of Initial Public Offering

Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share for aggregate gross ...

Odonate Therapeutics Announces Closing of Initial Public Offering

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share. The aggregate gross proceeds f...

Odonate Therapeutics Announces Initiation of CONTESSA, a Phase III Study of Tesetaxel in Patients...

In patients with MBC, tesetaxel was shown to have robust single-agent antitumor activity in two, multicenter, Phase 2 studies.

Odonate down after $150M IPO

Odonate raises $150M IPO

Odonate starts Phase III trial of tesetaxel to treat breast cancer

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13032018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly known as Odonate Therapeutics LLC, is a pharmaceutical company which develops medicines for the treatment of cancer. It develops best in class medicines that enhance and extend the lives of patients suffering from cancer. Odonate's lead product candidate, tesetaxel, is a novel orally administered taxane used for the treatment of various cancers. Te...

Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on tesetaxel at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1 – 5, 201...

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2017. As of December 31, 2017, Odonate had $198.1 million in cash, compared to ...

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2018. As of March 31, 2018, Odonate had $195.2 million in cash, compared to $198.1 mil...

Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - MarketResearch.biz

MarketResearch.biz announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives Therapeutics), By Read more...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12.39. The stock Read more...

Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

Argos Therapeutics Durham, North Carolinaheadquartered Argos Therapeutics Inc.'s stock finished last Friday's session 3.20% higher at $0.15. A total volume of 1.81 million Read more...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases Read more...

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Anika Therapeutics currently has a consensus target price of $62.50, indicating a potential upside of 16.84%.

What You Need to Know About DMD Therapeutics

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, ...

Alexion to Acquire Wilson Therapeutics and its Rare Liver Disorder Drug

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Wilson Therapeutics AB (publ) announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. Wilson Therapeutics is a biopharmaceutical com...

3 Biotech Stocks That Exploded in 2017

Biotech companies Nektar Therapeutics, Esperion Therapeutics, and Sangamo Therapeutics led the market this year.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks